NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG (OTC:RLFTF, SIX:RLF) today announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 (Aviptadil) in patients with Critical COVID-19 with respiratory failure.
The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19. At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.
This first interim analysis was focused on verifying the apparent safety of the drug in the first 30 patients and the feasibility of the study to reach its endpoint. The committee determined that the study appeared capable of reaching a statistically significant endpoint within its 144 patient sample size and voted for the study to continue until its next scheduled evaluation in four weeks.
The committee is composed of Prof. Alfred Sommer, MD, MHS, Dean Emeritus of the Johns Hopkins Bloomberg School of Public Health, Prof. Rita Colwell, PhD, former Director of the National Science Foundation, and Congressman, Andy Harris, MD, MHS (MD District 1) a part time Professor of Anesthesia and Critical Care at Johns Hopkins School of Medicine.
RLF-100 (Aviptadil) received Fast Track designation from the US FDA for the treatment of Critical COVID-19 with respiratory failure. Aviptadil is a synthetic form of human Vasoactive Intestinal Peptide (VIP) which is known to protect the Alveolar Type II cell of the lung from many forms of injury. This cell is critical to transmission of oxygen to the blood and is the site of attack for the Coronavirus.
“This milestone represents the extraordinary effort of our partners and collaborators at the University of Miami, Houston Methodist Hospital, UC Irvine, and University of Louisville who gave 100% to providing patients with Critical COVID-19 a chance to benefit from a potentially life-saving drug. We thank the members of the Data Monitoring Committee for devoting their valuable time to performing this vital role in helping to evaluate the safety and effectiveness of RLF-100,” said Prof. Jonathan C Javitt, MD, MPH, CEO of NeuroRx and the National Study Chair.
Details of the study are posted on clinicaltrials.gov NCT04311697.
About RLF-100
RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is primarily concentrated in the lung and is known to protect against a variety of lung injuries. VIP was awarded Orphan Drug Designation in 2001 by the U.S. FDA for treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. The European Medicines Agency awarded orphan drug designation in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis.
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent1 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
|
1 US 8,178,489 Formulation for Aviptadil |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200715005954/en/
Contact information
CORPORATE CONTACTS
Jonathan C. Javitt, M.D., MPH
Chief Executive Officer
NeuroRx, Inc.
ceo@neurorxpharma.com
Yves Sagot, Ph.D.
Relief Therapeutics Holding, SA
yves.sagot@relieftherapeutics.com
MEDIA CONTACT
Gloria Gasaatura
LifeSci Communications
ggasaatura@lifescicomms.com
646-970-4688
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Matrix Executions Unveils White-Label Equity Options Algos: True Customization for Broker-Dealers16.9.2025 14:45:00 EEST | Press release
Matrix Executions, a leader in options trading technology, announced its latest launch of its white-label equity options algorithmic trading solutions. This product empowers broker dealers with true customization and control, enabling them to offer a bespoke algo trading experience to their clients. The product leverages Matrix Executions’ advanced execution algo suite overlayed with the Matrix QRX ATS for an all-in-one answer to execution customization. In today's dynamic market, a one-size-fits-all approach no longer works. Matrix Executions’ offering provides broker dealers with the ability to define, configure, and deploy option algorithms with varying levels of precision. This isn't just a re-skinned product but a foundation for dynamic innovation. The Matrix white-label solution provides extensive bespoke parameter configurations and true customization. Their robust strategy configuration library allows broker-dealers to fine-tune specific variables to optimize performance for di
Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations16.9.2025 14:38:00 EEST | Press release
Tecnotree, a global leader in AI, 5G, and cloud-native digital platforms and services has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916788293/en/ Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations We feel this underscores the company’s ability to deliver AI-powered, cloud-native platforms that enable communications service providers (CSPs) and enterprises worldwide to accelerate digital transformation, monetize networks, and deliver hyper-personalized customer experiences. The Gartner report, authored by analysts Pulkit Pandey, Amresh Nandan, Will Rice, and Mounish Rai, evaluates leading AI vendors for CSP customer and business operations. According to Gartner, AI in CSP customer and business operations helps CSPs utilize AI/ML to generate ins
TreviPay Powers Walmart Business Pay By Invoice Offering16.9.2025 14:00:00 EEST | Press release
TreviPay, a fully managed B2B payments platform, has collaborated with Walmart Business to launch the next phase of the retailer’s Pay By Invoice program. The program enables eligible business customers to access a line of credit with 30-day net terms, powered by TreviPay’s next-generation payments and A/R automation technology. The offering is available for purchases online, in the Walmart Business app or in-store. A study of 300 global business buyers, conducted by Murphy Research for TreviPay, found 85% of buyers want the option to pay on net terms and are likely to buy more when they can pay this way. TreviPay’s Pay by Invoice offering enables buyers to defer payment, receive detailed invoices for streamlined recordkeeping and procurement, and manage cash flow more effectively. “The biggest opportunity in retail now is in B2B. Companies that capture this valuable segment will win with flexible payment options that integrate directly into the buying experience and maintain efficienc
Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma16.9.2025 14:00:00 EEST | Press release
Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with eosinophilic asthma. “More than half of people with asthma have the eosinophilic subtype, yet there remains a profound need for easily administered oral treatment options that can help address their symptoms, which are often severe,” said Ian Pavord, MA, DM, Professor of Respiratory Medicine at the University of Oxford, UK and a member of Areteia’s Scientific Advisory Board. “Initial results from the Phase III EXHALE-4 study are extremely promising, particularly the statistically significant improvement in lung function and the reduction in eosinophils observed with dexpramipexole versus placebo, which show the potential for dexpramipexole to become the first oral treatment approved for eosinophilic asthma.” “We are pleased to report positive topline results for the EXHALE-4 Phase III study, which
NIQ Joins the Decentriq Network to Enable Secure Data Collaboration for Marketers and Agencies Across Europe16.9.2025 13:00:00 EEST | Press release
NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expanding its services to the data and media ecosystem through privacy-persevering clean rooms, opening up new opportunities for marketing and advertising agencies to enrich their first-party data insights, inform audience strategies, and measure sales outcomes. As Pierre Cholet, Chief Customer Officer at Decentriq, explains, “NIQ has long been a trusted name in understanding consumer purchasing behavior. Now, by integrating their data into Decentriq’s clean room, advertisers and agencies can leverage thi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom